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Using Pyrene to Probe the Effects of Poloxamer Stabilisers on 
Internal Lipid Microenvironments in Solid Lipid Nanoparticles  
Jessica M. Taylor, a Kyle Scale, a Sarah Arrowsmith, b Andy Sharp, c Steve Rannard a and T.O. 
McDonald. a*
Solid lipid nanoparticles (SLNs) have proved to be effective 
nanocarriers with many advantages over other non-lipid-based 
systems. The development of new SLN formulations is often 
hindered through poor drug loading capacity and time-consuming 
optimisation of lipid/stabiliser combinations. Herein, we report the 
use of pyrene to probe the internal lipid microenvironment inside 
SLNs. We investigate the effect of using different poloxamer 
stabilisers on the internal polarity of SLNs formied using the 
common solid lipid, Compritol 888 ATO. We show that the internal 
lipid environment is controlled by the length of the poly(propylene 
oxide block) of poloxamer stabiliser, with longer blocks producing 
SLNs with less polar lipid cores. Blending of stabilisers could also be 
used to tune the polarity of the core lipid environment, which may 
allow for adjusting the polarity of the lipid to assist the loading of 
different therapeutics.  
Nanomedicine has offered the potential to improve the 
pharmacological profiles of poorly performing or poorly soluble 
medicines.1 Solid lipid nanoparticles (SLNs) are a type of 
nanomedicine that is composed of a lipid core that remains 
solid at body temperature and an active pharmaceutical 
ingredient (API).2–4 The hydrophobic lipid/API cores are 
stabilised by amphiphilic stabilisers such as poloxamers (often 
known by the brand names Pluronics® or Synperonic®), which 
are triblock copolymers of polyethylene oxide-polypropylene 
oxide-polyethylene oxide blocks (PEO-PPO-PEO) (Figure 1).5,6 
They have shown a high degree of versatility as stabilisers due 
to their low biological toxicity and ability to enhance the 
solubilisation of lipophilic compounds.7 They have improved 
pharmacological profiles of several poorly performing small 
molecule drugs and are the most common stabilisers used in 
SLN formulations.5,6 Compritol 888 ATO is one of the most 
commonly lipids used within SLNs.  
 
Figure 1: Solid lipid nanoparticles (SLNs) composed on an amphiphilic stabiliser (in this 
case poloxamers) and a solid lipid core. Poloxamers are triblock copolymers of 
polyethylene oxide-polypropylene oxide-polyethylene oxide blocks (PEO-PPO-PEO). The 
more hydrophobic PPO block will preferentially interact with the lipid core while the PEO 
blocks extend into the continuous phase and provide steric stabilisation. Compritol 888 
ATO is a common solid lipid and is made of a mixture of mono, di and triglycerides of 
behenic acid. 
This solid lipid is a mixture of mono, di and triglycerides of 
behenic acid (Figure 1), has been well documented showing 
high encapsulation efficiencies of still several hydrophobic 
entities including triamcinolone acetonide (99%), acyclovir (56-
81%), natamycin (85%) and indomethacin (72%).8–12 
Interestingly, all of these formulations also share a mutual 
secondary excipient, a poloxamer, Pluronic® F68 as an 
amphiphilic stabiliser. It is known that the incorporation of APIs 
within the core of SLNs disrupts the natural crystallinity of the 
lipid, potentially facilitating a more controlled, site specific 
release of the API.13–16 SLNs can be produced by a number of 
methods including hot, cold or high speed homogenisation, 
ultrasonication, spray drying and nanoprecipitation.17 Of these 
methods, nanoprecipitation is a particularly attractive method 
due to practical simplicity and scalability, as well as time and 
cost effectiveness.18–22 Nevertheless, there are still some 
challenges to address in the development of SLNs. A common 
drawback is as a result of low drug loading capacity compared to 
some other nanocarrier systems.13,23–25 This limitation is 
typically associated with poor compatibility between the 
crystalline lipid and the API mixture resulting in phase 
separation in the core.13,15,26 To address these drawbacks, 
a. Department of Chemistry, University of Liverpool, Crown Street, Liverpool,  L69 
7ZD, UK. 
b. Department of Cellular and Molecular Physiology, Institute of Translational 
Medicine, Liverpool Women’s Hospital, Crown Street, University of Liverpool, 
Liverpool, L8 7SS, UK. 
c. Department of Women’s and Children’s Health, Liverpool Women’s Liverpool 
Women’s Hospital, Crown Street, University of Liverpool, Liverpool, L8 7SS, UK. 
Electronic Supplementary Information (ESI) available: [details of any supplementary 
information available should be included here]. See DOI: 10.1039/x0xx00000x 
COMMUNICATION Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
considerable optimisation of the SLN formulation is typically 
required involving the screening different compositions and 
stabilisers, which typically involve time-consuming trial and error 
methods. It is known that the stabilisers can influence the 
internal polarity of the environment inside nanoparticles, which 
might influence the drug loading behaviour.27 Thus, there is a 
need obtain an understanding how the selection of stabilisers 
influences the polarity of the lipid core microenvironment. This 
understanding may be used to enhance the lipid/API affinity 
and reduce API partitioning. For example, if the relevant API is 
highly hydrophobic, the lipid environment should be 
hydrophobic also; however, if the API contains some polar 
character, then the lipid environment might be tuned to 
accommodate a more polarity in the lipid core 
microenvironment. Changes in polarity of the core environment 
can be observed through implementing pyrene as a fluorescent 
probe. Pyrene is a small molecule that has a unique, polarity 
dependent emission spectra, that consists of five defined 
vibrational emission bands (I1-I5). The first polarity dependent 
band (I1) and the third polarity independent band (I3), gives a 
ratio (I1/I3), which fluctuates to a lower value with an increase 
of hydrophobicity.5,28–32 As pyrene is highly hydrophobic, it 
partitions into the lipid phase in SLN systems and therefore 
provides relevant information on the polarity of the lipid core 
and the effect that different stabilisers have on this environment.
 Once an understanding is developed of how stabiliser 
properties influence the polarity of the SLN cores, this knowledge 
can then be translated to maximise drug loading and chose 
stabilisers suited to the lipid/API combination.  
 In this study, we have chosen to investigate the influence of 
poloxamer stabilisers and their effect on the polarity of the core 
made of the common solid lipid, Compritol 888 ATO (Figure 1). 
Within the family of poloxamer stabilisers (>50 polymers) there 
is huge variability in the hydrophilic-lipophilic balance (HLB) 
values, molecular weight and PPO/PEO ratios. We have 
therefore selected four poloxamers, commonly used in SLN 
formulations, (Pluronic® P105, F127, L64 and F68) to compare 
the influence of their HLB, molecular weight and PPO/PEO ratio 
(Table 1) on their ability to produce stable SLNs and their 
influence on the polarity of the SLN core microenvironment. 
 Firstly, blank SLNs were prepared in triplicate to show 
reproducibility and allow comparison of all physical properties 
of the solid lipid nanoparticles with and without pyrene. The 
following nanoprecipitation method was used; Compritol 888 
ATO (18 mg, 4.5 w/v%) was heated to 82°C in 1-propanol (4 mL) 
for 5 minutes. The aqueous phase (20 mL) containing the 
poloxamer stabiliser (16 mg, 0.8 w/v %) was agitated using 
mechanical stirring at 350 rpm and warmed to 26°C. The heated 
hydrophobic phase was then rapidly injected into the aqueous 
phase and stirred for a further 5 minutes. To obtain pyrene 
loaded particles, the method was repeated where pyrene (0.34 
mg) was incorporated into the hydrophobic lipid phase in 1-
propanol prior to injection. These methods resulted in either 
blank SLNs with a mass composition of Compritol 888 ATO (53 
wt%) and poloxamers stabilisers (47 wt%), or pyrene-SLNs 
containing an additional 0.34 mg of pyrene at 0.1 wt% of the 
total solid mass. All nanoprecipitations resulted in a dispersion 
in a water and 1-propanol mixed solvent system (5:1). The 
particles were analysed by dynamic light scattering (DLS) in 
order to determine the size distribution and mean diameter. 
Fluorescence measurements were undertaken to assess the 
polarity of the pyrene probe. For full experimental details see 
the electronic supplementary information (ESI), Section E1.  
 Each poloxamer was investigated for its effect on mean 
particle diameter (Dz), polydispersity index (PdI) and changes in 
internal core polarity. Particle size analysis showed monomodal 
particle size distributions for both the blank and pyrene-loaded 
SLNs. All SLNs had very similar mean diameters, 230 ± 27 nm for 
unloaded SLNs, and 242 ± 48 nm pyrene-loaded SLNs regardless 
of the poloxamer used as the stabiliser (Figure 2 and ESI, Figure 
S1). This therefore revealed that the different poloxamer 
stabilisers had little influence on formation of the SLNs and that 
there was no significant difference in particle size upon the 
incorporation of pyrene. This meant that any differences in the 
polarity of the SLNs prepared with the different stabilisers 
would be due to the environment inside the lipid core rather 
than differences in the size of the particles.  
Table 1: The poloxamers stabilisers chosen to investigate their effect on lipid core polarity. This table contains cited HLB and CMC data from Figueiras et al. 33  Poloxamers are ordered 


















e/m ratio of SLN 
dispersions 
1 P105 PEO37-PPO56- 
PEO37 
6500 6.2 x 10-6 15 0.76 1.63 ± 
0.07 




12600 2.8 x 10-6 22 0.33 1.66 ± 
0.01 
1.32 ± 0.03 0.21 
3 F68 PEO76-PPO29- 
PEO76 
8400 4.8 x 10-4 29 0.20 1.72 ± 
0.02 
1.39 ± 0.005 0.17 
4 L64 PEO13-PPO30- 
PEO13 
2900 4.8 x 10-4 15 1.2 1.70 ± 
0.001 
1.40 ± 0.01 0.15 
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Figure 2: The monomodal size intensity distributions of pyrene loaded solid lipid 
nanoparticles.  
 The fluorescence emission behaviour of pyrene and its link 
to polarity was then investigated with the comparison of three 
different solvent environments: pure water, water and 1-
propanol mixed (5:1) (the environment formed after 
nanoprecipitation) and pure 1-propanol. (ESI, Figure S2). The 
resulting I1/I3 values showed the differences in the polarities 
provided by the different solvents with values of 2.18 ± 0.09, 
1.78 ± 0.003 and 1.21 ± 0.002 for pure water, water and 1-
propanol mixed (5:1) and pure propanol respectively, showing 
that increased water content would increase the polarity 
around the pyrene molecules. All subsequent samples were 
measured with a mixed solvent continuous phase of water and 
1-propanol mixed (5:1). The effect of the different poloxamers 
on polarity environment was then assessed. Firstly, 
nanoprecipitations of pyrene were carried out into the poloxamer 
solutions without lipid present to give forming micellar solutions. 
All the poloxamers were used at the same concentration (0.8 
mg/ml) as used for SLN preparation. The resulting micellar 
solutions were significantly less turbid than SLN dispersions (ESI, 
Figure S3). Comparison of the I1/I3 values for pyrene showed that 
all micelles of the different poloxamers had values ranging from 
1.63-1.72 (ESI, Figure S4), slightly less polar than the mixed 
solvent continuous phase itself. This result indicated that some 
of the pyrene had partitioned into the hydrophobic PPO cores 
of the micelles. Out of the four different poloxamers, F68 and 
L64 the two stabilisers with the shortest PPO blocks (Figure 3A) 
showed the most polar internal environments (Figure 3B). 
Pyrene-loaded SLNs were then prepared using the four different 
poloxamer stabilisers and their I1/I3 values for pyrene-loaded 
SLNs prepared were recorded. The incorporation of the lipid 
resulted in a considerable reduction in the I1/I3 values to 1.30-
1.40 for all poloxamer stabilisers compared to the micellar 
solutions (Figure 3B).  
 The significant difference in the pyrene fluorescence 
between aqueous micellar solutions and SLNs can be attributed 
to the hydrophobic nature of Compritol 888 ATO and its ability 
to entrap hydrophobic molecules, in between the C22 alkyl 
chains.34–36 As with the I1/I3 data for the micelles, it was clear 
that there were noticeable similarities in the I1/I3 values for F68 
and L64 compared to F127 and P105 both in the micellar 
solutions and in SLN dispersions. The PPO blocks of the 
poloxamers will adsorb and interact with the lipid core, while 
the PEO chains will extend into the continuous phase and 
provide steric stabilisation. It was apparent that the molecular 
weight of the hydrophobic PPO units is a dominant factor for 
controlling the polarity inside the lipid cores of the SLNs. The 
poloxamers with longer hydrophobic blocks, F127 (PPO= 65) 
and P105 (PPO= 56) showed significantly lower I1/I3 ratios in 
comparison to poloxamers with shorter PPO blocks, L64 (PPO= 
30) and F68 (PPO= 29). This change in polarity can be attributed 
PPO chains partitioning into the lipid core and reducing the 
internal polarity. While F127 possess a longer PPO block 
compared to P105, it did not have the lowest average I1/I3 value 
at 1.32 ± 0.03 vs P105 at 1.30 ± 0.02. This can potentially be 
attributed to the much larger PEO block of F127 (PEO=200) 
compared to P105 (PEO=74) causing increased steric hindrance 
between the F127 units which might potentially limit the extent 
to which PPO block of F127 can associate with the lipid core. 
This result showed that the polarity inside the lipid cores of the 
SLNs was being controlled by the length of the PPO block of the 
poloxamer.  
 The hydrophilic-lipophilic balance (HLB) is used often used 
to predict the properties and potential uses of stabilisers.37 As 
shown in Table 1, Pluronic® P105 and L64 have the same cited 
HLB value of 15.33 However, P105 and L64 stabilised SLNs had 
significantly different I1/I3 values of 1.30 ± 0.02 and 1.40 ± 0.01 
and therefore it can be concluded the HLB is not a viable 
parameter to predict microenvironment polarity. This suggests 
that there was very limited incorporation of PEO component of 
the stabilisers into the lipid core; if there was greater 
incorporation of the PEO component of the poloxamer then the 
I1/I3 value should have been highest for the stabilisers with the 
highest HLB value. The difference in the I1/I3 values could 
potentially be a result of the average fluorescence signal from 
the pyrene encapsulated in the lipid cores of the SLNs and any 
pyrene encapsulated in the micelles. In order to investigate this 
the samples were centrifuged and the supernatant was 
analysed in the absence of the SLNs (ESI, Figure S5). Any 
fluorescence from the supernatant would represent the pyrene 
contained in the micelles. However, the supernatant was found 
to display very limited fluorescence with ill-defined emission 
spectra. This finding revealed that the pyrene was 
predominantly encapsulated within the lipid cores of the SLNs 
independent of the stabiliser used.  
The difference in lipid/stabiliser behaviour of these SLN samples 
was also apparent from the excimer emission which was 
observed at 440-500 nm in the pyrene emission spectra (Figure 
3C). This is a fundamental feature in pyrene fluorescence with 
reported  intermolecular spatial proximity within ≤3.5 Å.38 The 
poloxamers F127 and P105 (those with the longest PPO blocks) 
exhibited more intense excimer emissions signifying a stronger 
spatial proximity to other pyrene monomers within the lipid 
core, coupled with a higher excimer/monomer (e/m) ratio 
(Table 1).15  
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Figure 3: The fluorescence emission behaviour of SLNs with different poloxamer stabilisers. (A) Schematic representation on the different poloxamers and their interaction with a 
lipid core. (B) Comparison of I1/I3 data between different poloxamer stabilisers in the presence of a lipid core or as aqueous solution forming micelles. (C) Fluorescence emission 
spectra for four different samples of SLNs prepared with for each poloxamer stabiliser (normalised against I1). Shows the difference in I1/I3 values for each poloxamer stabiliser, 
emphasising the importance of the lipid core from key differences in the excimer emission (440-500 nm). 
 The e/m ratio is a secondary feature of the excimer emission 
where the height of the excimer peak (~465-470 nm) is divided 
by the polarity independent peak, I1. Previous experiments have 
showed that  e/m  ratios are correlated to the extent of spatial 
proximity and flexibility of pyrene molecules.39  A larger e/m 
ratio and excimer emission is due to  increased intermolecular 
coupling of excited pyrene molecules that are more spatially 
proximal.39 On the contrary, Pluronic F68 and L64 SLNs both 
exhibit lower intensity excimer emissions and e/m ratios. As 
previously outlined, our findings suggest adsorption of the PPO 
block onto the lipid core due to the PEO chains having negligible 
impact on the internal microenvironment. Therefore, the higher 
excimer emission and e/m ratios for F127 and P105 suggests 
that the hydrophobic guest molecules are located towards the 
surface of the lipid core rather than homogeneously distributed 
throughout the lipid matrix. These findings, coupled with the 
I1/I3 polarity differences, propose that pyrene is more densely 
packed in SLNs with a less polar lipid core microenvironments 
and spatial entrapment of guest molecules is largely influenced 
through the poloxamer PPO block length. These findings are of 
significant importance as this shows that the choice of 
poloxamer stabilisers used can profoundly impact the internal 
polarity of SLNs, without causing a significant difference in the 
size and PdI of the dispersions. More interestingly, this also 
introduces a new concept of lipid core polarity tuning which has 
potential to aid drug loading in future formulations.  
 Blends of poloxamers are commonly used in formulating 
SLNs and therefore the effect of blending poloxamers of 
different PPO block length on the internal core 
microenvironment was investigated (for blending details see ESI 
Table S6). No notable difference in the size or PdI of the 
resulting SLNs for the blends were observed (ESI Figure S7). 
 
Figure 3. The effect of blending of the different Pluronic® stabilisers on the I1/I3 ratio for 
pyrene loaded SLNs. This shows the effect of varying of the composition of F68 blends 
with either F127 or P105, showing that increasing the F68 content increases the polarity 
inside the SLN when using over 50 wt%. 
When F127 and P105 were blended (ESI, Figure S8), it was 
evident that there was a negligible difference in the polarity 
environment for the SLNs which can be accredited to their 
similar number of PPO units (65 and 56 respectively). When F68, 
the poloxamer with shortest PPO block (29), was blended with 
either of the poloxamer with longer PPO blocks (F127 (65) or 
P105 (56)), substantial changes in the polarity of the lipid cores 
was found (Figure 3). With an increase in the amount of F68 in 
the blend (PPO=29) in both cases caused a notable increase in 
the polarity of the internal lipid core demonstrating tuneability 
on Compritol 888 ATO cores and should be taken into 
consideration during formulation development of drug loaded 
systems.  
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 In this study we have shown that pyrene can be used as a 
fluorescent probe to investigate the polarity inside SLNs. We 
have found that the length of the PPO block in the stabiliser has 
a significant impact on the polarity inside the lipid core, with this 
having a larger impact than the HLB of the stabilisers. This 
understanding of the influence of the length of the PPO block 
on the polarity inside of the lipid core will be important in the 
design of SLNs. It may offer the potential to tune the internal 
environment to enhance drug loading and drug release 
behaviour. 
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